RARE
RARE
US90400D1081
Ultragenyx Pharmaceutical Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 673.000.000 560.000.000
20.2%
Cost of Revenue 109.000.000 77.000.000
41.6%
Gross Profit 564.000.000 483.000.000
16.8%
1.099.000.000 1.019.000.000
7.9%
Operating Income -535.000.000 -536.000.000
0.2%
Pretax Income -571.000.000 -567.000.000
0.7%
Net Income Common Stockholders -575.000.000 -569.000.000
1.1%
-- --
--
-- --
--
ende